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and 3 concluded to a non signiﬁcant effect. The qualitative evalua-
tion provided a median of 61% for the clinical data and of 50% for 
the FDG-PET data. SUV measurement and threshold for deﬁning 
high SUV were study dependent, 7 studies looked for a “best” cut-off 
(maximizing the logrank test statistic) however without adjusting the 
p value for multiplicity. Overall, the combined HR for the 12 reports 
was 2.29 (95% CI: 1.62-3.23) and test for heterogeneity was signiﬁcant 
(p=0.02); excluding the studies proposing a “best” cut-off, it decreased 
to 2.15 (95% CI: 1.16-3.97) but remained signiﬁcant (7 studies, n=475 
patients).
Conclusion: Our MA suggests that SUV max measured on primary 
tumor has a prognostic value in NSCLC; these results should be 
conﬁrmed in a MA based on individual patients data allowing to deﬁne 
more homogeneous groups in terms of SUV acquisition methods and 
timing, to perform a multivariate analysis adjusted for known and 
reproducible prognostic factors, to look more adequately at the deﬁni-
tion of high SUV and to take into account data from studies not fully 
dedicated to histologically proven lung cancer or from unpublished 
research works.
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Purpose: Approximately 20-40% of patients with surgically resected 
stage I non-small cell lung cancer will develop recurrent disease. There 
are no reliable markers that can identify those patients at highest risk of 
recurrence, who might beneﬁt from adjuvant therapy. Positron emission 
tomography (PET) with the glucose analogue 2-[18F] ﬂuoro-2-deoxy-
D-glucose (FDG) is used commonly in the staging of NSCLC. The 
primary tumor uptake of FDG assessed as the standardized uptake 
value (SUV) correlates with tumor doubling time. The purpose of this 
study was to determine whether the preoperative maximum tumor SUV 
(SUVmax) would predict eventual relapse in patients with resected 
stage I NSCLC.
Methods: We identiﬁed consecutive patients who had undergone cura-
tive surgical resection for stage I NSCLC (excluding pure bronchioloal-
veolar carcinoma) between 1999 and 2003 and who had preoperative 
FDG-PET imaging. Patients were divided into two equal cohorts based 
on SUVmax (above and below the median for the group). Recurrence 
rates for each cohort were estimated by the Kaplan-Meier method. 
Deaths without evidence of recurrence were treated as censoring 
events. Overall survival was calculated as a secondary endpoint. 
Results: Of 136 patients who met inclusion criteria, 77 (57%) had T1 
and 59 (43%) had T2 tumors. The median follow-up duration was 46 
months. The median SUVmax was 5.5. The estimated 5-year recur-
rence rates for patients with low SUVmax (< 5.5 ) and high SUVmax 
(≥ 5.5) were 13% and 36% respectively (p=0.002), with 5-year overall 
survival rates of 74% and 52% respectively (p=0.006). In stage IA pa-
tients, SUVmax was associated with a trend toward higher recurrence 
rates (12% vs 25%, p=0.14), and in stage IB patients SUVmax strongly 
correlated with recurrence (17% vs 46%, p=0.018). In a multivariate 
analysis for predictors of recurrence based on SUVmax, T classiﬁca-
tion, tumor size, age, and histology, only SUVmax was a statistically 
signiﬁcant predictor of recurrence (HR=2.9, p=0.008). 
Conclusions: High SUVmax (≥ 5.5) on preoperative FDG-PET is an 
independent predictor of relapse in resectable stage I NSCLC. Prospec-
tive trials of adjuvant chemotherapy in patients with stage I NSCLC 
and high SUVmax should be conducted.
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Background: Survival advantages have been demonstrated for 
advanced BAC patients with ipsilateral intrapulmonary metastasis at 
diagnosis, but it is not known whether these differences manifest in 
non-BAC NSCLC patients. 
Methods: We conducted a case-only analysis of U.S. Surveillance, Epi-
demiology, and End Results (SEER) data (1999-2003). Overall survival 
(OS) and lung cancer-speciﬁc survival (LCSS) univariate analyses were 
conducted using the Kaplan-Meier method. Multivariate survival analy-
ses were performed using Cox proportional hazards ratios. 
Results: 46,169 incident cases of histologically-conﬁrmed non-BAC 
NSCLC with complete TNM staging information available were identi-
ﬁed, including large cell carcinoma (LCC, n=1826, or 6.7%), squamous 
cell carcinoma (SqCC, n=5956, or 21.7%), undifferentiated carcinoma 
(n=8754, or 31.9%), and adenocarcinoma (n=10,899, or 39.7%). The 
majority of these NSCLC cases had advanced stage at presentation 
(stage I, n=11,106; stage II, n=1908; stage IIIa, n=5720; stage IIIb, 
n=7845; stage IV, n=19,590). Cases with stage IIIB non-BAC-NSCLC 
due to multiple lesions in the same lobe (n=633) had signiﬁcantly 
improved median OS (21 m) and LCSS (31m) compared to other stage 
IIIB NSCLC cases (n=7212; OS = 8 m, LCSS =9 m) (P<0.0001 for 
both OS and LCSS comparisons) (Figure 1). Among stage IV NSCLC 
cases, those with intrapulmonary metastasis (n=3010) had signiﬁcantly 
improved median OS (9m) and LCSS (11m) compared to those with 
distant metastasis (n=16,580; OS = 5m, LCSS = 6m) (P<0.0001 for 
both comparisons) (Figure 2). These survival differences persisted after 
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adjustment for age, gender, ethnicity, and surgical treatment. Among 
stage IV NSCLC cases, those with ipsilateral intrapulmonary metasta-
sis (n=1120) had improved OS (13m) compared to those with bilateral 
intrapulmonary metastasis (n=1890; OS=7m) (P < 0.0001) (Figure 2).
Conclusions: Among stage IIIB and IV NSCLC cases, those present-
ing with ipsilateral intrapulmonary metastasis have improved survival 
outcomes. Our results add further support for modiﬁcation to the cur-
rent non-small-cell lung cancer staging system.
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Purpose: To evaluate the usefulness of FDG-PET/CT (PET/CT), supe-
rior to CT, for determining tumor response to treatment after stereotac-
tic radiosurgery (SRS) in primary or metastatic lung cancer
Methods: Thirty-ﬁve patients, with lung tumor, treated with SRS 
between July 2004 and June 2006 were reviewed. Treatment aim was 
curative or salvage in 30 primary or recurrent lung cancer patients, 
palliative in 15 metastatic lung cancer patients. SRS delivered 36, 48, 
or 60 Gy radiation, 12 or 20 Gy per fraction, to gross tumor with 5mm 
margin for 3 or 4 days consecutively. PET/CT was checked twice for 
measuring changes of maximal standardized uptake value (SUVmax), 
1 or 2 months before and after SRS, and CT was checked coincidently. 
Evaluation of tumor response with PET/CT used a level of SUV 
change, and response criteria were divided into complete remission 
(CR; maximal SUV decrease ≥70%), partial remission (PR; 10-69% 
decrease), no response (NR; 10% decrease-10% increase), and disease 
progression (PD; >10% increase)
Results: SUVmax value in PET/CT before and after SRS were 
0.80-13.10 (median 5.3) and background uptake-7.20 (median 1.70) 
respectively. Decrease rate of SUVmax was (-25.0)-98.3% (median 
50.0%). Metabolic response judged by PET/CT was CR in 17 (37.8%), 
PR in 19 (42.2%), NR in 8 (17.8%), and PD in 1 (2.2%) patients. Clini-
cal response judged by CT was CR in 2 (4.4%), PR in 18 (45.0%), NR 
in 20 (44.5%), PD in 5 (11.1%) patients. Peritumoral radiation induced 
pneumonitis or ﬁbrosis was a confounding factor for evaluation with 
CT especially in PD or NR groups, but PET/CT could differentiate such 
inﬂammatory lesion with actual tumor progression in some patients.
Conclusion: PET/CT at 1 month after SRS could reﬂect actual re-
sponse better than CT examined coincidently. FDG-PET/CT at 1 month 
before and after SRS might be a useful modality for evaluation of 
tumor response after treatment
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Background: We showed that PCG signiﬁcantly increases both 
Response Rate (RR) (43.6% vs 20%) and median survival time (10.8 
mo vs 8.3 mo) over PC and that at Cox analysis, the only independent 
prognostic factors were PS and Treatment (Paccagnella et al, J Clin 
Oncol 2006;24: 681-687).
According to the Prentice criteria (Stat Med 1989;8: 431-440), to 
directly relate Response and Survival it is necessarily that Responding 
patients (and non Responding) for both arms have a similar survival 
and that the survival difference between the two arms disappear when 
the Response Factor is included in the Multivariate Analysis.
Methods: Out of 324 pts included in the original analysis, 26 pts not 
evaluable for response (early death, toxicity, refusal) before the planned 
response evaluation at two months were excluded (15 pts from PC arm 
and 11 pts from PCG arm). The analysis was however also performed 
considering the no evaluable patients as non responders.
Results: Overall, Responder patients had a median Survival that nearly 
doubled that of no Responders: 14.73 mo vs 7.67 mo (HR: 0.49; CI: 
0.31 - 0.54; P= 0.000). 
No Responders pts from PC and PCG arms had a similar survival (me-
dian 7.53 mo and 8.07 mo respectively; P= 0.96) as well as respond-
ers (CR + PR) patients (median 14.13 mo and 15.40 mo respectively; 
P=0.38).
The only difference between the two arms was that more than the 
double of patients in PCG arm responded (43.6% vs 20%) and conse-
